- Home
- SOPA vs VIVS Comparison
SOPA vs VIVS Comparison
Compare SOPA & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPA
- VIVS
- Stock Information
- Founded
- SOPA 2018
- VIVS 2007
- Country
- SOPA Singapore
- VIVS United States
- Employees
- SOPA N/A
- VIVS N/A
- Industry
- SOPA EDP Services
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOPA Technology
- VIVS Health Care
- Exchange
- SOPA Nasdaq
- VIVS Nasdaq
- Market Cap
- SOPA 3.8M
- VIVS 4.2M
- IPO Year
- SOPA 2021
- VIVS N/A
- Fundamental
- Price
- SOPA $1.37
- VIVS $1.45
- Analyst Decision
- SOPA Strong Buy
- VIVS
- Analyst Count
- SOPA 1
- VIVS 0
- Target Price
- SOPA $15.00
- VIVS N/A
- AVG Volume (30 Days)
- SOPA 148.5K
- VIVS 46.6K
- Earning Date
- SOPA 08-18-2025
- VIVS 07-11-2025
- Dividend Yield
- SOPA N/A
- VIVS N/A
- EPS Growth
- SOPA N/A
- VIVS N/A
- EPS
- SOPA N/A
- VIVS N/A
- Revenue
- SOPA $6,731,955.00
- VIVS $144,000.00
- Revenue This Year
- SOPA N/A
- VIVS $42.38
- Revenue Next Year
- SOPA $45.16
- VIVS $15.42
- P/E Ratio
- SOPA N/A
- VIVS N/A
- Revenue Growth
- SOPA N/A
- VIVS 32.11
- 52 Week Low
- SOPA $0.64
- VIVS $1.41
- 52 Week High
- SOPA $6.75
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- SOPA 52.00
- VIVS N/A
- Support Level
- SOPA $1.21
- VIVS N/A
- Resistance Level
- SOPA $1.48
- VIVS N/A
- Average True Range (ATR)
- SOPA 0.10
- VIVS 0.00
- MACD
- SOPA -0.01
- VIVS 0.00
- Stochastic Oscillator
- SOPA 41.38
- VIVS 0.00
About SOPA Society Pass Incorporated
Society Pass Inc is building an ecosystem of platforms and technology-enabled companies that synergistically work together to transform how consumers and merchants interact with one another in Southeast Asia and South Asia. Through the acquisition of companies and partnerships with entrepreneurs, the company meets the growing demand for services in sectors such as lifestyle, beauty, travel, and food and beverage. The company currently operates in Six reportable operating segments: Online Grocery and Food deliveries, Digital marketing, Online ticketing and reservation, Telecommunications Reseller, e-commerce, and Corporate. The company generates the majority of its revenue from the Digital marketing segment.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.